Lanean...
Regulatory considerations in oncologic biosimilar drug development
Biosimilar monoclonal antibodies are being developed globally for patients with different types of solid tumors and hematologic malignancies. Applications for proposed biosimilar monoclonal antibodies are being submitted to the regulatory authorities around the world and may increase patient access...
Gorde:
| Argitaratua izan da: | MAbs |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622730/ https://ncbi.nlm.nih.gov/pubmed/25961747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1040973 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|